Latest Headlines

  1. Quiver Bioscience Secures Non-Dilutive Funding To Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities And Advance Powerful AI/ML-Based In Vitro / In Silico Predictor Of CNS Drug Safety 7/1/2025

    Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, today announced receipt of a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

  2. Healx And SCI Ventures Join Forces To Uncover Cures For Paralysis With AI-Driven Drug Discovery 7/1/2025

    Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate the discovery and development of therapies for spinal cord injury (SCI) using artificial intelligence.

  3. New Potential Drug Targets For Multiple Sclerosis Identified 7/1/2025

    A new study published in the journal PNAS by researchers at the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential drug targets for the treatment of multiple sclerosis.

  4. Rocket Pharmaceuticals Announces FDA IND Clearance Of RP-A701 For The Treatment Of BAG3-Associated Dilated Cardiomyopathy 6/30/2025

    Rocket Pharmaceuticals, Inc., a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated Dilated Cardiomyopathy (BAG3-DCM), a severe form of heart failure characterized by progressive ventricular enlargement and impaired systolic function.

  5. Riliprubart Granted Orphan Drug Designation In Japan For Chronic Inflammatory Demyelinating Polyneuropathy 6/30/2025

    The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to riliprubart, a monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway for people with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite available therapies, many CIDP patients are left with residual symptoms, including weakness, numbness, and fatigue that can lead to long-term morbidity and diminished quality of life. Approximately 30% of people with CIDP do not respond to standard therapies.

  6. Alpha Fusion, Inc. And Curadh MTR, Inc. To Enter Into Strategic Partnership To Advance Global Development Of Astatine-211 Based Radiopharmaceuticals 6/30/2025

    Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration combines Alpha Fusion's leading role in At-211 drug discovery and early clinical work in Japan, with Curadh's global expertise in radiopharmaceutical development.

  7. XtalPi And Pfizer Expand Strategic Collaboration To Advance AI-Driven Drug Discovery And Materials Science Simulations 6/29/2025

    XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with Pfizer to pioneer a next-generation molecular modeling platform for drug discovery.

  8. St. Jude Algorithm Puts Water To Work In Drug Discovery 6/27/2025

    Every protein in the body is encased in a water shell that directs protein structure, provides vital stability and steers function. Because of this, water molecules represent a powerful but largely underappreciated foothold in drug binding studies.

  9. Cancer Drug Candidate Developed Using Supercomputing & AI Blocks Tumor Growth Without Toxic Side Effect 6/26/2025

    A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics) and the Frederick National Laboratory for Cancer Research (FNLCR) has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect.

  10. Grace Therapeutics Announces Submission Of New Drug Application To U.S. Food And Drug Administration For GTx-104 6/25/2025

    Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced the submission to the U.S. Food and Drug Administration (FDA) of the Company’s New Drug Application (NDA) for GTx-104.